Holen Sie sich die Stockscreener-App
13.82
9.77%
1.23
Schlusskurs vom Vortag:
$12.59
Offen:
$12.89
24-Stunden-Volumen:
323.07K
Relative Volume:
3.73
Marktkapitalisierung:
$366.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.59M
KGV:
-10.84
EPS:
-1.275
Netto-Cashflow:
$-18.35M
1W Leistung:
+31.49%
1M Leistung:
+32.88%
6M Leistung:
+73.18%
1J Leistung:
+71.68%
1-Tages-Spanne:
$12.67
$14.16
1-Wochen-Bereich:
$10.11
$14.16
52-Wochen-Spanne:
$5.55
$14.16
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
13.82 | 366.58M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Nuvectis Pharma Inc (NVCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvectis Pharma Inc (NVCT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nuvectis Pharma Inc (NVCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvectis Pharma Inc (NVCT) Institutional Confidence - TradingKey
Nuvectis Pharma Inc (NVCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvectis Pharma Inc (NVCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nuvectis Pharma Inc (NVCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Nuvectis Pharma Inc (NVCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NVCT Q1 2026 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue StatusRevenue Per Share - newsline.com
NVCT Maintained by HC Wainwright & Co. -- Price Target Raised to $13.00 - GuruFocus
Nuvectis Shareholders Approve Director Election and Auditor Ratification - TipRanks
Nuvectis Pharma (NVCT) director granted 35,000 restricted common shares - Stock Titan
Nuvectis Pharma (NVCT) director awarded 35,000 restricted shares, now holds 122,828 - Stock Titan
Nuvectis Pharma (NVCT) grants director Juan Sanchez 35,000 restricted shares - Stock Titan
Nuvectis Pharma (NVCT) director awarded 35,000 restricted common shares in Form 4 filing - Stock Titan
[8-K] Nuvectis Pharma, Inc. Reports Material Event - Stock Titan
Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright - TipRanks
NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reinforces Cost DisciplinePost-Earnings Reaction - newsline.com
Nuvectis Pharma (NVCT) Rallies 1.94% as Stock Tests Key Resistance at $11.04Long Short Pair - newsline.com
Analyst Reiterates Buy on Nuvectis Pharma, Maintains $17 Price Target on NXP900 Pipeline Upside and Favorable M&A Read‑Through - TipRanks
(NVCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
NVCT Q1 2026 Earnings: Narrower Loss Beats Estimates as Pre-Revenue Biotech Advances PipelineProfit Inflection Point - newsline.com
NVCT Q1 2026 Earnings: Smaller-Than-Expected Loss Highlights Cost DisciplineSegment Revenue Breakdown - newsline.com
NVCT Q1 2026 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Analysis - newsline.com
Responsive Playbooks and the NVCT Inflection - Stock Traders Daily
NVCT Q1 2026 Earnings: Beat on EPS Despite No RevenueMargin Compression Risk - newsline.com
NVCT Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesEBITDA Margin Trends - newsline.com
Nuvectis Pharma (NVCT) Declines 5.39% as Stock Tests Key Support LevelIchimoku Cloud - thelegaladvocate.com
Wall Street analysts think Nuvectis Pharma (NVCT) could surge 57%: Read this before placing a bet - MSN
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet - sharewise.com
NVCT Q1 2026 Earnings: Better-than-Expected Loss Narrower as Company Advances PipelineRevenue Growth Outlook - newsline.com
Nuvectis Pharma (NVCT) Surges +2.82%, Nearing $11.48 Resistance 2026-05-21IV Contraction - Newser
Understanding the Setup: (NVCT) and Scalable Risk - Stock Traders Daily
NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma set to participate in key investor event at NASDAQ - Traders Union
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor ... - Caledonian Record
Number of shareholders of Nuvectis Pharma, Inc. – NASDAQ:NVCT - TradingView
Number of shareholders of Nuvectis Pharma, Inc. – BOATS:NVCT - TradingView
TradingKey - TradingKey
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - MSN
Nuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66 - MSN
The Technical Signals Behind (NVCT) That Institutions Follow - Stock Traders Daily
What Nuvectis Pharma (NVCT) does that creates lasting value (Creeps Higher) 2026-05-08Momentum Investing - newser.com
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Should I buy Nuvectis Pharma (NVCT) - Zacks Investment Research
Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth - simplywall.st
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvectis Pharma | 10-Q: Q1 2026 Earnings Report - Moomoo
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):